Laboratory

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Retrieved on: 
Monday, April 1, 2024
University, Automation, Gene, Drug discovery, Cell Press, DNA, Artificial intelligence, SLAS, Society, Laboratory, CRISPR, Cell

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.

Key Points: 
  • TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.
  • The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns.
  • In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.
  • "Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte.

Koel USA Inc. Selects Univar Solutions to Represent Specialty Pigment and Dyes Portfolio

Retrieved on: 
Monday, April 1, 2024
CARE, Skin care, Partnership, Beauty, Univar Solutions, Food and Drug Administration, Accreditation, Transport, Laboratory, Cosmetics, Marketing, USFDA, Food, Individual

DOWNERS GROVE, Ill., April 1, 2024 /PRNewswire/ -- Univar Solutions, LLC (Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, today announced Koel USA Inc., a subsidiary of Koel Colours Private Ltd. ("Koel Colours"), has chosen Univar Solutions to exclusively distribute its pigments and colorants used in cosmetics and personal care formulations. Koel Colours is a leading global cosmetic pigment manufacturer for the beauty and personal care industry with a full range of colorant solutions, including organic, effect, and specialty pigments, water-based pigment dispersions, water soluble dyes, and oil soluble and natural colorants.

Key Points: 
  • With the increased demand for beauty and personal care products, Univar Solutions strengthens its portfolio of cosmetic pigments to offer even more innovative color solutions for customers in the United States
    DOWNERS GROVE, Ill., April 1, 2024 /PRNewswire/ -- Univar Solutions, LLC (Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, today announced Koel USA Inc., a subsidiary of Koel Colours Private Ltd. ("Koel Colours"), has chosen Univar Solutions to exclusively distribute its pigments and colorants used in cosmetics and personal care formulations.
  • Koel Colours is a leading global cosmetic pigment manufacturer for the beauty and personal care industry with a full range of colorant solutions, including organic, effect, and specialty pigments, water-based pigment dispersions, water soluble dyes, and oil soluble and natural colorants.
  • "As a leading global distributor of specialty ingredients, we recognize the growing worldwide need for high quality sustainable color cosmetic products.
  • With dyes, pigments, and specialty color solutions that also impact performance, Univar Solutions' beauty expertise knows no bounds.

Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Productivity, Oversight Committee, Elanco, Innovation, Growth, Abbott Laboratories, Trupanion, Strategic planning, Idexx Laboratories, Laboratory, ELAN, Fortification, Management

GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members.

Key Points: 
  • New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee
    GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members.
  • Ms. Turner brings significant global experience in both the animal health and broader healthcare industries.
  • Mr. Wallace is a well-respected animal health leader with more than 30 years of executive experience at companies such as Fort Dodge Animal Health, Trupanion and Ceva.
  • "We are pleased to welcome Kathy and Craig, both accomplished animal health industry executives, to the Elanco Board," said Jeff Simmons, President and CEO of Elanco Animal Health.

Second Opinion Expert Announces Strategic Relationship With Genome International

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Genomics, SOE, Pharmacogenomics, Genome, Patient, Clinical decision support system, Research, Hospital, Laboratory, Whole genome sequencing, Medicine, CDSS, Therapy, Physician, Antibiotics

LOS ANGELES, April 1, 2024 /PRNewswire/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that it has entered into a strategic relationship with Genome International to provide rapid Whole Genome Interpretation (WGI™) delivered by Genome Explorer®, a comprehensive Clinical Decision Support System that brings genomic information to the point of care.

Key Points: 
  • We are proud to be part of Genome International's revolutionary effort to put the power of the genome in the hands of healthcare practitioners worldwide.
  • SOE will assist Genome International with business development and strategy, leveraging SOE's relationships and expertise.
  • Genome Explorer® provides a single unified platform for whole genome variant interpretation with high accuracy and success across diseases.
  • "We are proud to be part of Genome International's revolutionary effort to put the power of the genome in the hands of healthcare practitioners worldwide."

Shanghai continues to improve as one of China's most dynamic cities

Retrieved on: 
Wednesday, March 27, 2024
Museum, Laboratory, Quality of life, Life, Yangtze Delta, City, Culture, Research, Science, PwC, GDP, Film industry

The report, a collaboration between the China Development Research Foundation and global consulting firm PricewaterhouseCoopers (PwC), offers a comprehensive assessment of 57 cities across 10 dimensions and 50 variables.

Key Points: 
  • The report, a collaboration between the China Development Research Foundation and global consulting firm PricewaterhouseCoopers (PwC), offers a comprehensive assessment of 57 cities across 10 dimensions and 50 variables.
  • In terms of culture and quality of life, Shanghai continues to lead nationwide.
  • The report further emphasizes the increasing significance of cities in the Yangtze River Delta, highlighting notable progress for cities like Suzhou and Hangzhou.
  • PwC notes that the overall strong performance of the Yangtze River Delta cities underscores the region's balanced and mature development, positioning it as a key economic growth pole.

Laboratory Information Management System (LIMS) Market Size to Grow by USD 907.08 million from 2023 to 2027, Market growth at 9.08% CAGR expected during the forecast period, Technavio

Retrieved on: 
Tuesday, March 26, 2024
Cloud, PerkinElmer, Laboratory information management system, Informatics, Component, Health, Paperless office, Laboratory, Saas, Automation, Thermo Fisher Scientific, Risk, ROW, ISO 17025, Privacy, Data management, Documentation, Biobank, LIMS, Research, AI, Food, Machine learning, ISO/IEC 17025, Growth, Abbott Laboratories, ERP, Software, Illumina, Inc., Comp, Life, ISO, Hardware

By geography, the global laboratory information management system (lims) market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Key Points: 
  • By geography, the global laboratory information management system (lims) market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global laboratory information management system (lims) market.
  • Driving Forces in the LIMS Market:
    Stringent compliance and governmental regulations propel the growth of the Laboratory Management System (LIMS) market.
  • Growth of the Laboratory Information Management System (LIMS) Market industry across North America, Europe, Asia, and Rest of World (ROW)
    Gain instant access to 17,000+ market research reports.

Government of Canada invests in laboratories to support science in Canada

Retrieved on: 
Tuesday, March 26, 2024
Health, Government, Tax, Canadian Food Inspection Agency, Science, The Honourable, Research, RSS, Laboratory, Plant, Engineering, Indigenous peoples, Public service, Animal, Food safety, Regulation, Pharmaceutical industry

This project will provide federal scientists across several departments and agencies with a leading-edge, multi-purpose, sustainable and collaborative facility to complement existing government science laboratories and capabilities.

Key Points: 
  • This project will provide federal scientists across several departments and agencies with a leading-edge, multi-purpose, sustainable and collaborative facility to complement existing government science laboratories and capabilities.
  • "Today's announcement is one of many steps the Government of Canada is taking towards building state-of-the-art science and research facilities across the country.
  • Laboratories Canada is a long-term strategy that will deliver on the vision to strengthen federal science in Canada.
  • The Laboratories Canada strategy includes the development of 5 science hubs that will support science program synergies across the country and the RSS hub, which includes the RSS Main Project, is one of these key science hubs.

The Clinical and Laboratory Standards Institute Announces the Publication of New Antimicrobial Susceptibility Testing Documents CLSI M100-Ed34, M02-Ed14, and M07-Ed12

Retrieved on: 
Tuesday, March 26, 2024
M11, Quality control, Government, Communication, Doctor of Pharmacy, Clinical, Committee, CLSI, Accreditation, Salmonella, Table, Laboratory, M02, M07, Microbiology, Patient safety, Multimedia, Medical device

MALVERN, Pa., March 26, 2024 /PRNewswire/ -- The Clinical and Laboratory Standards Institute (CLSI) has released a new update of CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition and revised editions of CLSI M02—Performance Standards for Antimicrobial Disk Susceptibility Tests, 14th Edition and CLSI M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 12th Edition .

Key Points: 
  • MALVERN, Pa., March 26, 2024 /PRNewswire/ -- The Clinical and Laboratory Standards Institute (CLSI) has released a new update of CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition and revised editions of CLSI M02—Performance Standards for Antimicrobial Disk Susceptibility Tests, 14th Edition and CLSI M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 12th Edition .
  • The tables presented in CLSI M100 represent the most current information for drug selection, interpretation, and quality control using the procedures defined in CLSI standards CLSI M02 , M07 , and M11 .
  • Users should replace previously published tables with the new edition of CLSI M100 to ensure accurate testing and patient safety.
  • In addition, CLSI will host its annual What's New in the 2024 CLSI Standards for Antimicrobial Susceptibility Testing webinar on 17 April 2024 from 1:00-2:30 PM ET.

CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews

Retrieved on: 
Tuesday, March 26, 2024
Arthralgia, Chamomile, Health, Ginger, Antioxidant, Glucosamine, Relaxation, SAN, Research, Anxiety, Rose hip, Laboratory, Anti-inflammatory, Dog, Safety, Pet, OTCQB, Animal, NASC, Cannabidiol, Pharmaceutical industry

SAN DIEGO, March 26, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, proudly announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the industry-leading +PlusCBD lineup are now available nationwide at select retailers and from our website at www.pluscbdoil.com.

Key Points: 
  • The latest additions to the industry-leading +PlusCBD lineup are now available nationwide at select retailers and from our website at www.pluscbdoil.com .
  • The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being.
  • With a THC-free formulation and non-psychoactive properties, our chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions.
  • +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024.

Clinical Study Reveals The Fresh Test™ is Preferred Diagnostic Beverage by 100 Percent of Participants

Retrieved on: 
Monday, March 25, 2024
Laboratory, Glucose, LOS, Patient, Labcorp, Nausea, Hospital, FDA, Taste, Fresh, GMO, AACC, Trial of the century, Prenatal care, University

LOS ANGELES, March 25, 2024 /PRNewswire-PRWeb/ -- A comprehensive IRB Clinical Study, spearheaded by a prestigious laboratory and University, has showcased a unanimous preference for The Fresh Test™ over traditional glucose testing beverages. Designed for expecting individuals keen on healthier dietary inputs without compromising on taste, The Fresh Test™ offers a unique solution to glucose testing in 2024.

Key Points: 
  • LOS ANGELES, March 25, 2024 /PRNewswire-PRWeb/ -- A comprehensive IRB Clinical Study, spearheaded by a prestigious laboratory and University, has showcased a unanimous preference for The Fresh Test™ over traditional glucose testing beverages.
  • Designed for expecting individuals keen on healthier dietary inputs without compromising on taste, The Fresh Test™ offers a unique solution to glucose testing in 2024.
  • Remarkably, 100 percent of study participants favored The Fresh Test™ , citing its high-quality, additive-free composition that notably reduces nausea.
  • Endorsed by leading hospitals and laboratories, including LabCorp, The Fresh Test™ is recognized for its innovative approach to prenatal screening.